Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) saw unusually-strong trading volume on Wednesday . Approximately 270,123 shares changed hands during trading, an increase of 9% from the previous session’s volume of 248,183 shares.The stock last traded at $18.62 and had previously closed at $19.28.

Several analysts have recently commented on NTLA shares. Jefferies Group restated a “buy” rating and set a $33.00 price objective on shares of Intellia Therapeutics in a research report on Wednesday, August 17th. Zacks Investment Research downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. Wedbush restated an “outperform” rating and set a $38.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, August 23rd. Leerink Swann upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $32.00 price objective on the stock in a research report on Friday, August 5th. Finally, Credit Suisse Group AG started coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $35.50.

The company’s market cap is $673.11 million. The stock’s 50 day moving average price is $20.17 and its 200 day moving average price is $22.46.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/intellia-therapeutics-inc-ntla-sees-unusually-high-trading-volume-2.html

A number of hedge funds have recently added to or reduced their stakes in NTLA. GLG Partners LP bought a new stake in Intellia Therapeutics during the second quarter worth $100,000. Pacad Investment Ltd. bought a new stake in Intellia Therapeutics during the second quarter worth $117,000. Metropolitan Life Insurance Co. NY bought a new stake in Intellia Therapeutics during the second quarter worth $190,000. Teachers Advisors Inc. bought a new stake in Intellia Therapeutics during the second quarter worth $235,000. Finally, Marshall Wace LLP bought a new stake in Intellia Therapeutics during the second quarter worth $244,000.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

5 Day Chart for NASDAQ:NTLA

Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.